Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study

Blood (2024) 144 (Supplement 1): 4187.

https://doi.org/10.1182/blood-2024-209138

Published: 2024

Journal Articles

Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 “Sublime” Study

Blood (2024) 144 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2024-209043

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

Blood (2024) 144 (11): 1193–1205.

https://doi.org/10.1182/blood.2024024283

Published: 2024

Includes: Supplemental data

Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Blood (2023) 142 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2023-178473

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Sarah Elitzur, Ruth Shiloh, Jan Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Stephane Ducassou, Nizar Mahlaoui, Marion Strullu, Thomas Lehrnbecher, Kjeld Schmiegelow, Oussama Abla, Liliia Anderzhanova, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Francesco Ceppi, Nicole Bodmer, Triantafyllia Brozou, Luciano Dalla-Pozza, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Sarah K. Tasian, Thai Hoa Tran, Marek Ussowicz, Jose Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Ronit Nirel, Veronique Minard-Colin, Andishe Attarbaschi, Arndt Borkhardt

Blood (2023) 142 (Supplement 1): 520.

https://doi.org/10.1182/blood-2023-179333

Published: 2023

Journal Articles

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Blood (2022) 140 (Supplement 1): 8971–8972.

https://doi.org/10.1182/blood-2022-168568

Published: 2022

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

Low Level BCR-ABL1 G ene Fusion Detected By RT-PCR in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia Does Not Predict Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at Relapse: A 10-Year Single Institution Study

Lucy E Cain, BSc, MBBS, MPH, Oksana Mirochnik, Michael M Stevens, MBBS FRACP, Stewart J Kellie, MBBS FRACP MDMIntPH(Hons), Bhavna Padhye, MBBS FRACP MClinTRes PhD, Steven J Keogh, MBBS(Hons) FRACP, Dinisha Govender, MBChB FRACP, Jessica Ryan, BMed(Hons) FRACP, Luciano Dalla-Pozza, MBBS FRACP, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139359

Published: 2020

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL)

Alexander A Morley, MD, Sue Latham, BSc, Elizabeth Hughes, BSc, Bradley Budgen, BSc, Matthew Greenwood, FRACP, FRCPA, Kenneth F Bradstock, Luciano Dalla-Pozza, MBBS FRACP, Tamara Law, PhD, Louise Doculara, BSc, Nicola Venn, BSc, Rosemary Sutton, PhD

Blood (2018) 132 (Supplement 1): 2831.

https://doi.org/10.1182/blood-2018-99-110123

Published: 2018

Journal Articles

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

Blood (2018) 132 (3): 264–276.

https://doi.org/10.1182/blood-2017-12-821363

Published: 2018

Includes: Supplemental data

Journal Articles

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

Weili Sun, Timothy Triche, Jr, Jemily Malvar, Paul Gaynon, Richard Sposto, Xiaojing Yang, Henrique Bittencourt, Andrew E. Place, Yoav Messinger, Chris Fraser, Luciano Dalla-Pozza, Bodour Salhia, Peter Jones, Alan S. Wayne, Lia Gore, Todd M. Cooper, Gangning Liang

Blood (2018) 131 (10): 1145–1148.

https://doi.org/10.1182/blood-2017-09-803809

Published: 2018

Includes: Supplemental data

Journal Articles

Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy

Marion K Mateos, MBBS FRACP, Toby N Trahair, MBBS FRACP PhD, Chelsea Mayoh, BSc, Pasquale M Barbaro, MBBS FRACP FRCPA, Carly George, MBBS, FRACP, Rosemary Sutton, PhD, Tamas Revesz, MDPhDD.Sc FRACP FRCPA, Draga Barbaric, MBBS FRACP, Jodie Giles, Frank Alvaro, FRACP, MBBS, Francoise Marie Mechinaud, MD FRACP, Daniel R Catchpoole, PhD BSc, Rishi Sury Kotecha, MBBChir, MRCP, FRACP, PhD, Michael CJ Quinn, BSc MSc PhD, Georgia Chenevix-Trench, BSc PhD, Stuart MacGregor, BSc MSc PhD, Luciano Dalla-Pozza, MBBS FRACP, Glenn M Marshall, MBBS, MD FRACP

Blood (2017) 130 (Supplement 1): 2102.

https://doi.org/10.1182/blood.V130.Suppl_1.2102.2102

Published: 2017

Journal Articles

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

Ondrej Hrusak, MD PhD, Valerie De Haas, MD PhD, Ales Luks, Iveta Janotova, Ester Mejstrikova, MD PhD, Kirsten Bleckmann, MD, Anja Moricke, MD, Julie Irving, PhD, Benigna Konatkowska, Thomas B. Alexander, MD MPH, Hiroto Inaba, MD PhD, Kjeld Schmiegelow, MD DMSc, Simone Stokley, FRCPath,, Jorge Gabriel Rossi, PhD, Maria Sara Felice, MD PhD, Luciano Dalla-Pozza, MB BS FRACP, Jessa Morales, Michael Dworzak, MD, Barbara Buldini, MD, Giuseppe Basso, Myriam Campbell, Maria Elena Cabrera, Neda Marinov, Sarah Elitzur, MD, Shai Izraeli, MD, Drorit Luria, PhD, Tamar Feuerstein, PhD, Alexandra Kolenova, MD PhD, Peter Svec, Elena Kreminska, Karen R. Rabin, MD, Sophia Polychronopoulou, MD PhD, Elaine da Costa, Hanne Vibeke Marquart, MD PhD, Antonis Kattamis, MD, Richard Ratei, Dirk Reinhardt, MD PhD, Anthony V Moorman, PhD, Martin Schrappe, MD, Jan Stary, MD D.Sc.

Blood (2016) 128 (22): 584.

https://doi.org/10.1182/blood.V128.22.584.584

Published: 2016

NARROW

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study

Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 “Sublime” Study

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Low Level BCR-ABL1 G ene Fusion Detected By RT-PCR in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia Does Not Predict Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at Relapse: A 10-Year Single Institution Study

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL)

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia

A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium

Clinical and Germline Risk Factors for the Occurrence of Multiple Treatment Toxicities during Childhood Acute Lymphoblastic Leukemia (ALL) Therapy

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only